Athena Athena

X
[{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7 Hills Pharma Announces FDA Clearance of Investigational New Drug Application for 7HP349, a First-in-Class Immune Stimulant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7 Hills Pharma Announces Coronavirus Vaccine Program\nTargeting At-Risk Elderly ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7 Hills Pharma Announces Positive Data With Oral Immunostimulant to Improve Effectiveness of COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7 Hills Pharma Awarded Pioneering Patent Estate Covering Integrin Activators to Improve Effectiveness of Immunotherapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7 Hills Pharma Announces First Healthy Volunteers Dosed in Landmark Phase 1 Trial of Immunostimulant to Improve Immuno-Oncology Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7 Hills Pharma\u2019s Clinical-stage Novel Immunostimulant 7HP349 Granted FDA Fast Track Designation for Anti-PD-1-resistant Metastatic Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Texas Heart Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Demonstrates Integrin Activation Can Bring the Heat to Cold Melanoma Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7 Hills Pharma Expands Pioneering Patent Portfolio With New Claims Covering Innovative Combination Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"7 Hills Pharma Receives $3MM SBIR Grant from NIAID to Accelerate Novel Vaccine Combination Against Chagas Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"CPRIT","pharmaFlowCategory":"D","amount":"$13.5 million","upfrontCash":"Undisclosed","newsHeadline":"7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by 7 Hills Pharma

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The fundings will be used to advance 7HP349 (alintegimod), its first-in-class oral selective integrin activator into a Phase 1b/2a clinical trial in patients who are resistant to PD-1-based therapies.

            Lead Product(s): Alintegimod

            Therapeutic Area: Oncology Product Name: 7HP349

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: CPRIT

            Deal Size: $13.5 million Upfront Cash: Undisclosed

            Deal Type: Funding May 22, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            DNA-based vaccine to protect against Tc infection, which was tested in preclinical models in combination with 7HP’s lead, oral immunostimulant. Results of this initial study, demonstrated that the combination therapy was effective in both prophylactic and therapeutic settings.

            Lead Product(s): DNA-based Vaccine,7HP349

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases

            Deal Size: $3.0 million Upfront Cash: Undisclosed

            Deal Type: Funding August 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            7HP349 is 7HP’s lead, clinical-stage integrin agonist. It is a first-in-class, orally delivered small molecule that safely and selectively activates the integrins LFA-1 and VLA-4 to augment the antigen-specific immune response.

            Lead Product(s): 7HP349

            Therapeutic Area: Oncology Product Name: 7HP349

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 09, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            7HP349 is 7HP’s lead, clinical-stage integrin agonist. It is a first-in-class, orally delivered small molecule that safely and selectively activates the integrins LFA-1 and VLA-4 to augment the antigen-specific immune response.

            Lead Product(s): 7HP349

            Therapeutic Area: Oncology Product Name: 7HP349

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Texas Heart Institute

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 18, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            7HP349, an allosteric activator of integrins VLA-4 and LFA-1, used in combination with immunotherapy improve effectiveness of potentially any immunotherapeutic, including, but not limited to immune checkpoint inhibitors and infectious disease vaccines.

            Lead Product(s): 7HP349,Undisclosed

            Therapeutic Area: Oncology Product Name: 7HP349

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 08, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            7HP349 is designed to activate integrins, enhancing cell adhesion for stronger immune responses to vaccinations, such as those for COVID-19 and influenza, and immuno-oncology drugs, such as checkpoint inhibitors.

            Lead Product(s): 7HP349

            Therapeutic Area: Oncology Product Name: 7HP349

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            7 Hills Pharma’s oral small molecule integrin activators directly promote cell adhesion, which is essential for immune system activation and for strengthening antigen specific immune responses of immunotherapies.

            Lead Product(s): 7HP349

            Therapeutic Area: Infections and Infectious Diseases Product Name: 7HP349

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 04, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Preclinical studies reveal 7HP349 significantly increases IgG binding antibodies with a vaccine targeting SARS-CoV-2. The data also suggest 7HP349 can be used as an immunostimulant for any COVID-19 vaccine and has the potential to accelerate immune system response.

            Lead Product(s): 7HP349

            Therapeutic Area: Infections and Infectious Diseases Product Name: 7HP349

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 07, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            7 Hills Pharma is launching an evaluation of its lead compound 7HP349, a next-generation small molecule integrin activator, as an oral adjuvant with a novel recombinant coonavirus vaccine.

            Lead Product(s): 7HP349

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 15, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            U.S. FDA has cleared the company’s investigational new drug application for 7HP349. The FDA completed its 30-day safety review and granted approval to proceed with Phase 1 healthy volunteer study.

            Lead Product(s): 7HP349

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 14, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY